Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2.

"the mapped rna sequence has been submitted to genbank previously (accession no mw041156) 2 2 vero e6 cells were maintained in complete emem [emem supplemented with 10% heat-inactivated fetal bovine serum (gibco; 10500-064) and 1% penicillin/streptomycin (gibco; 15140-122)] in t175 flasks (thermo fisher scientific waltham ma usa) at 37? table 2 mean synergy score (median [range]) zip"

"Competing interests AO is a Director of Tandem Nano Ltd. AO has received research funding from ViiV, Merck and Janssen, and consultancy fees from Gilead. These associations had no influence on the content of the current manuscript. PON is currently engaged in a collaboration with Romark LLC, but this interaction had no influence on the content of the current manuscript. No other conflicts of interest are declared by the authors."

"Funding This study was supported by the Medical Research Council (MR/836 S00467X/1, GAB and SAW) and the UK Research and Innovation Strength in Places Fund (SIPF 20197, GAB, SAW and GH). AO acknowledges research funding from Unitaid (LONGEVITY) and EPSRC (EP/R024804/1). The authors also acknowledge funding by the National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, the Centre of Excellence in Infectious Diseases Research and the Alder Hey Charity. In addition, the authors wish to acknowledge support from Liverpool Health Partners and the Liverpool-Malawi-COVID-19 Consortium."